MBX (MBX Biosciences) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is MBX Biosciences Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

MBX Biosciences's Capital Expenditure for the three months ended in Mar. 2025 was $-0.03 Mil. Its Operating Income for the three months ended in Mar. 2025 was $-26.53 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

MBX Biosciences Capex-to-Operating-Income Historical Data

The historical data trend for MBX Biosciences's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MBX Biosciences Capex-to-Operating-Income Chart

MBX Biosciences Annual Data

Trend

Dec22

Dec23

Dec24

Capex-to-Operating-Income

MBX Biosciences Quarterly Data
	Dec22	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Capex-to-Operating-Income	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of MBX Biosciences's Capex-to-Operating-Income

For the Biotechnology subindustry, MBX Biosciences's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MBX Biosciences's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MBX Biosciences's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where MBX Biosciences's Capex-to-Operating-Income falls into.

Save Embed

;

Save Embed

;

MBX Biosciences Capex-to-Operating-Income Calculation

MBX Biosciences's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.874)	/	-68.194
	=	N/A

MBX Biosciences's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.03)	/	-26.529
	=	N/A

MBX Biosciences (NAS:MBX) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

MBX Biosciences Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of MBX Biosciences's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

MBX Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MBX Biosciences Inc (NAS:MBX) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032

Website

https://www.mbxbio.com

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.